Status: Not yet recruiting
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
Participants needed: 140
Trial details
Phase: Phase 2Age: 45-80Biological sex: AllType: InterventionalSponsor: NeuroTrauma Sciences, LLCUpdated: Aug 3, 2026
Eligibility criteria
Acute ischemic stroke with moderate to severe hemiparesis [+4]
Pre-existing motor deficit prior to index stroke [+4]